Table I.
(a) Clinical data of our study’s included MS and control cohorts. (b) HLA data of our study’s included MS and control cohorts.
| 1(a) | |||||
|---|---|---|---|---|---|
|
| |||||
| Clinical data of the Oslo MS-control cohort |
MS patients from the Oslo MS registry |
Oslo MS patients genotyped |
Oslo controls genotyped |
UCSF MS patients genotyped |
UCSF controls genotyped |
| N = 1648 | N = 639 | N = 530 | N = 1997 | N = 708 | |
| Female, % | 68.5 | 73.0 | 68.6 | 73.0 | 52.7 |
| RRMS, % | 79.5a | 82.6 | 90.4 | ||
| PPMS, % | 20.5a | 17.4 | – | 8.5 | |
| AAO, mean (SE) | 32.4 (0.27)b | 32.4 (0.42) | – | 31.6 (0.21) | |
| Age at EDSS exam, mean (SE) | 49.1 (0.42)c | 50.2 (0.55) | – | 43.6 (0.24) | |
| OCB positive, % | 84.8d | 88.7d | 69.3d | ||
| EDSS, mean (SE) | 4.5 (0.09)c | 4.6 (0.12) | – | 3.49 (0.05) | |
| MSSS, mean (SE) | 4.76 (0.11)e | 4.80 (0.14) | – | 4.75 (0.06) | |
|
| |||||
| 1(b) | |||||
|
| |||||
| Associated HLA and DRB1 alleles in Oslo MS cohort subsetf |
Allele | Allele frequency in MS (%) |
Allele frequency in Control (%) |
p-value | |
|
| |||||
| 2n = 1156 | 2n = 698 | ||||
| HLA-A | *02 | 326 (28.2) | 236 (33.8) | 0.0092 | |
| *03 | 228 (19.7) | 108 (15.5) | 0.0251 | ||
| 2n = 1140 | 2n = 699 | ||||
| HLA-B | *07 | 285 (25) | 102 (14.6) | 0.0001 | |
| *44 | 58 (5.1) | 92 (13.2) | 0.0001 | ||
| 2n = 1211 | 2n = 625 | ||||
| HLA-C | *07 | 467 (39.3) | 178 (28.5) | 0.0001 | |
| *03 | 207 (17.4) | 133 (21.3) | 0.0428 | ||
| *06 | 63 (5.3) | 52 (8.3) | 0.0146 | ||
| 2n = 1183 | 2n = 700 | ||||
| HLA-DRB1 | *04 | 181 (15.3) | 156 (22.3) | 0.6119g | |
| *15 | 460 (38.8) | 103 (14.8) | 1*10−26 | ||
| *01 | 103 (8.7) | 88 (12.6) | 0.7536g | ||
| *13 | 100 (8.4) | 86 (12.3) | 0.7506g | ||
| *03 | 128 (10.8) | 83 (11.9) | 0.0824g | ||
| *07 | 68 (5.7) | 79 (11.3) | 0.0277g | ||
From 1485 patients.
From 1504 patients.
From 927 patients.
Based on 1293 patients in the Oslo MS registry, 568 genotyped patients from the Oslo MS registry and 760 patients from UCSF. OCB measured by isoelectric focusing and agarose gel electrophoresis.
From 735 patients.
Available classical HLA typing data for the included MS cases and controls, from the Oslo cohort.
HLA-DRB1*15 was excluded from the analysis.
AOO: Age at onset; EDSS: Expanded Disability Status Scale; HLA: human leukocyte antigen; MS: multiple sclerosis; MSSS: MS severity score; OCB: oligoclonal bands; PPMS: primary progressive MS; RRMS: relapsing–remitting MS; SE: standard error; UCSF: University of CA - San Francisco.